KMTS KESTRA MED TECHNOLOGIES LTD revenue, earnings and financials
For the quarter ended July 31, 2026, KESTRA MED TECHNOLOGIES LTD reported revenue of $31.0M (up 59.9% from a year earlier), net income of −$44.1M and diluted EPS of −$0.75; over the last four quarters revenue was $107M and net income −$150M; for the fiscal year ended April 2026 revenue was $95.1M, up 59.0% on the year before.
KMTS annual revenue and earnings
- Fiscal year ended Apr 2026: revenue $95.1M, gross profit $48.9M, operating income −$135M, net income −$132M (margin -138.4%), EPS −$2.43
- Fiscal year ended Apr 2025: revenue $59.8M, gross profit $24.2M, operating income −$106M, net income −$114M (margin -190.3%), EPS −$5.13
- Fiscal year ended Apr 2024: revenue $27.8M, gross profit $362K, operating income −$85.1M, net income −$94.1M (margin -338.4%), EPS −$5.07
KMTS quarterly revenue and earnings
- Quarter ended Jul 31, 2026: revenue $31.0M (up 59.9% year over year), net income −$44.1M, EPS −$0.75
- Quarter ended Apr 30, 2026 (from the annual report): revenue $28.6M (up 66.2% year over year), net income −$38.8M, EPS −$0.68
- Quarter ended Jan 31, 2026: revenue $24.6M (up 62.7% year over year), net income −$34.2M, EPS −$0.61
- Quarter ended Oct 31, 2025: revenue $22.6M (up 53.4% year over year), net income −$32.8M, EPS −$0.64
- Quarter ended Jul 31, 2025: revenue $19.4M (up 51.5% year over year), net income −$25.8M, EPS −$0.50
- Quarter ended Apr 30, 2025 (from the annual report): revenue $17.2M, net income −$52.1M, EPS −$1.57
- Quarter ended Jan 31, 2025: revenue $15.1M, net income −$21.5M, EPS −$1.25
- Quarter ended Oct 31, 2024: revenue $14.7M, net income −$20.4M, EPS −$1.19
- Quarter ended Jul 31, 2024: revenue $12.8M, net income −$19.9M, EPS −$1.12
KMTS cash flow, buybacks and dividends
- Fiscal year ended Apr 2026: operating cash flow −$81.7M, share buybacks n/a
- Fiscal year ended Apr 2025: operating cash flow −$77.6M, share buybacks n/a
- Fiscal year ended Apr 2024: operating cash flow −$72.2M, share buybacks n/a
KMTS balance sheet
- Jul 31, 2026: cash $68.6M, total assets $347M, total liabilities $125M, shareholders' equity n/a, long-term debt $72.5M
- Apr 30, 2026: cash $99.7M, total assets $358M, total liabilities $98.8M, shareholders' equity n/a, long-term debt $42.6M
- Jan 31, 2026: cash $291M, total assets $379M, total liabilities $91.4M, shareholders' equity n/a, long-term debt $42.3M
- Oct 31, 2025: cash $175M, total assets $247M, total liabilities $82.6M, shareholders' equity n/a, long-term debt $41.9M
- Jul 31, 2025: cash $201M, total assets $266M, total liabilities $82.1M, shareholders' equity n/a, long-term debt $41.5M
- Apr 30, 2025: cash $238M, total assets $296M, total liabilities $90.3M, shareholders' equity n/a, long-term debt $41.1M
- Apr 30, 2024: cash $8.25M, total assets $45.9M, total liabilities $78.2M, shareholders' equity n/a, long-term debt $42.5M
What is KMTS's revenue?
KESTRA MED TECHNOLOGIES LTD reported $107M of revenue over its last four quarters, through July 31, 2026.
Is KMTS profitable?
No. KESTRA MED TECHNOLOGIES LTD lost $150M over the last four quarters.
What is KMTS's EPS?
Diluted earnings per share over the last four quarters were −$2.68; −$0.75 in the latest quarter.